Meloxicam vs. Celecoxib for Personal Injury Pain: Which NSAID Is Right?

James Wong — Founder & Pharmacist, LienScripts | February 7, 2026 | 8 min read

Meloxicam and celecoxib are both COX-2-preferential or selective NSAIDs commonly prescribed after personal injury for musculoskeletal inflammation and joint pain. They differ in selectivity, GI risk profile, cardiovascular considerations, and clinical indications in ways that affect prescribing decisions in PI cases. Understanding these differences helps attorneys and patients make sense of what the pharmacy record is documenting.

NSAIDs in Personal Injury: Why COX-2 Agents Are Often Preferred

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications in personal injury cases. After a motor vehicle accident, slip-and-fall, or workplace injury, musculoskeletal inflammation — in soft tissue, joints, spinal structures, and periarticular tissue — is the primary driver of pain. NSAIDs address this directly by blocking the cyclooxygenase (COX) enzyme pathway that produces prostaglandins, the lipid mediators responsible for inflammatory pain, swelling, and tissue sensitization.

The traditional NSAIDs (ibuprofen, naproxen, diclofenac) block both COX-1 and COX-2 nonselectively. COX-1 is a constitutive enzyme that protects the gastric lining and supports platelet aggregation. COX-2 is the inducible enzyme primarily responsible for inflammatory prostaglandin production. Blocking COX-1 along with COX-2 is what produces the GI toxicity (ulcers, bleeding, gastric erosion) associated with traditional NSAIDs.

Meloxicam and celecoxib were developed to provide anti-inflammatory efficacy by targeting COX-2 more selectively, reducing — though not eliminating — the GI risks of traditional NSAIDs. In PI cases, they are often prescribed when:

The patient requires prolonged NSAID therapy (weeks to months, not days)
There are GI risk factors that make traditional NSAIDs dangerous
Musculoskeletal inflammation is the dominant pain driver
The physician wants an NSAID that can be taken once or twice daily for better adherence

Meloxicam: Preferential COX-2 Inhibition

Mechanism of Action

Meloxicam (brand name: Mobic) is classified as a preferential COX-2 inhibitor — it inhibits COX-2 to a greater degree than COX-1 at therapeutic doses, but it is not exclusively selective. At standard doses (7.5 mg/day), the COX-2:COX-1 inhibition ratio favors COX-2 significantly. At the maximum dose (15 mg/day), some COX-1 inhibition occurs, which modestly increases GI risk at the higher end.

Meloxicam belongs to the oxicam chemical class and is pharmacologically distinct from celecoxib despite the shared COX-2 preference.

FDA Approval and Indications

Meloxicam is FDA-approved for:

Osteoarthritis (OA)
Rheumatoid arthritis (RA)
Juvenile rheumatoid arthritis (JRA)

Its use in PI cases — for acute and subacute musculoskeletal injury pain — is off-label but extremely common and well-supported by evidence for musculoskeletal inflammation.

Dosing

Standard dose: 7.5 mg once daily
Maximum dose: 15 mg once daily
Once-daily dosing is a significant practical advantage for adherence in PI patients managing multiple medications

Clinical Profile in PI Cases

Strengths of meloxicam in PI:

Once-daily dosing simplifies a complex medication regimen
Generic availability makes it accessible and cost-effective under pharmacy lien
Long half-life (~20 hours) provides 24-hour anti-inflammatory coverage
Well-studied in musculoskeletal conditions with robust efficacy data
Lower GI risk than non-selective NSAIDs when used at 7.5 mg/day

Limitations:

Preferential but not selective — GI risk increases at 15 mg vs. 7.5 mg
Not appropriate for patients with severe renal impairment
Still carries cardiovascular risk, as all NSAIDs do
Not appropriate in the perioperative setting around surgery (platelet considerations)

[!KEY] Meloxicam's once-daily dosing and COX-2 preference make it the most commonly prescribed NSAID in PI cases with prolonged anti-inflammatory needs. When the pharmacy record shows meloxicam prescribed for weeks or months after an accident, it documents ongoing inflammatory activity — the physician is treating persistent, not resolved, musculoskeletal inflammation.

Celecoxib: Selective COX-2 Inhibition

Mechanism of Action

Celecoxib (brand name: Celebrex) is the only FDA-approved selective COX-2 inhibitor currently on the U.S. market. It binds COX-2 in a structurally selective manner that minimally affects COX-1 at therapeutic doses, providing anti-inflammatory analgesia with a significantly reduced effect on the gastric mucosal protection that COX-1 provides.

[!SOURCE] The clinical GI safety advantage of selective COX-2 inhibition over non-selective NSAIDs was established in the CLASS trial. See: Silverstein FE et al. "Gastrointestinal Toxicity with Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis." JAMA. 2000;284(10):1247-1255. PMID: 10979111.

FDA Approval and Indications

Celecoxib is FDA-approved for:

Osteoarthritis
Rheumatoid arthritis
Acute pain in adults
Primary dysmenorrhea
Ankylosing spondylitis
Juvenile rheumatoid arthritis

Notably, celecoxib has an FDA approval for acute pain — making it on-label for post-injury pain management in a way meloxicam is not. This is clinically relevant when the PI claim involves acute-phase pain management.

Dosing

For acute pain: 400 mg initially, then 200 mg as needed
For chronic musculoskeletal pain (OA/RA dosing pattern): 100–200 mg twice daily or 200 mg once daily
Twice-daily dosing at the maintenance schedule vs. meloxicam's once-daily is a practical consideration

Clinical Profile in PI Cases

Strengths of celecoxib in PI:

Selective COX-2 inhibition — lowest GI toxicity risk among NSAIDs
On-label for acute pain (unique among COX-2 agents)
Well-suited for patients with GI risk factors (prior ulcers, on anticoagulants, elderly)
Evidence for joint and synovial inflammation (post-traumatic arthritis, meniscal injury)
Available as generic (since 2014) — accessible under pharmacy lien

Limitations:

Twice-daily dosing at the maintenance schedule
Sulfonamide cross-reactivity — celecoxib contains a sulfonamide moiety; patients with sulfa drug allergies require careful evaluation before prescribing
Cardiovascular risk: celecoxib carries the same class-wide cardiovascular warning as all NSAIDs (increased risk of MI and stroke with prolonged use)
Higher cost than meloxicam prior to generic entry (now comparable)

GI Risk: The Key Clinical Distinction

The practical reason physicians choose celecoxib over meloxicam (or other NSAIDs) often comes down to GI risk management.

Risk Factor	Recommended NSAID Choice
No GI risk factors, short-term use	Any NSAID including non-selective
No GI risk factors, prolonged use	Meloxicam or celecoxib
GI risk factors (prior ulcer, age >65, anticoagulant use)	Celecoxib preferred; add PPI
High GI risk + need for NSAID	Celecoxib + PPI
Prior GI bleed on NSAID	Celecoxib + PPI (with extreme caution)

In PI cases, patients who were prescribed celecoxib rather than a non-selective NSAID or meloxicam have either a documented GI risk factor or a prescribing physician who proactively chose the most GI-protective agent for prolonged anti-inflammatory therapy. Either way, the choice documents a clinically deliberate decision.

The Role of PPI Co-Prescribing

Even with COX-2-preferential or selective NSAIDs, physicians frequently co-prescribe a proton pump inhibitor (PPI) — omeprazole, pantoprazole, or esomeprazole — for GI protection. In PI pharmacy records, a combination of meloxicam or celecoxib with a PPI is a clinical signal that:

The NSAID course is expected to be prolonged
The physician is actively managing GI risk
The patient's clinical picture warranted ongoing anti-inflammatory therapy significant enough to require GI prophylaxis

This prescribing pattern documents both the ongoing inflammatory injury and the physician's careful clinical management — relevant to both medical necessity documentation and the overall treatment narrative.

[!KEY] When the PI pharmacy record shows celecoxib or meloxicam alongside a proton pump inhibitor (omeprazole, pantoprazole), this combination documents that the treating physician anticipated prolonged NSAID use significant enough to require GI protection. This pairing is a clinical marker of sustained inflammatory injury, not a brief acute episode.

Cardiovascular Considerations

All NSAIDs, including meloxicam and celecoxib, carry an FDA black box warning for increased risk of serious cardiovascular events (myocardial infarction, stroke) with prolonged use. This risk increases with duration of therapy and pre-existing cardiovascular disease.

In PI cases involving older patients or those with cardiac history, the prescribing physician must weigh anti-inflammatory benefit against cardiovascular risk — a decision that may appear in chart notes and that attorneys should review when the NSAID course is prolonged.

Side-by-Side Comparison for PI Attorneys

Feature	Meloxicam	Celecoxib
COX selectivity	Preferential COX-2	Selective COX-2
FDA acute pain approval	No	Yes
Standard PI dosing	7.5–15 mg once daily	100–200 mg twice daily
GI risk	Lower than non-selective	Lowest among NSAIDs
Sulfa allergy concern	No	Yes (sulfonamide moiety)
Generic available	Yes (low cost)	Yes (since 2014)
Cardiovascular black box	Yes	Yes
Common in PI	Yes — most common NSAID	Yes — especially high-risk GI patients

Pharmacy Lien Coverage for Both NSAIDs

Both meloxicam and celecoxib are covered under pharmacy liens when prescribed by a treating physician for injury-related musculoskeletal inflammation and pain. Both are available as generics and are standard components of PI medication regimens.

In the POGOS, NSAID fill history — which agent, what dose, how long — provides a clear documentary record of inflammatory pain management duration. Physicians who continue refilling these medications month after month are documenting ongoing clinical findings of inflammation, not resolved injury.

Related Resources

Frequently Asked Questions

What is the difference between meloxicam and celecoxib for injury pain?

Meloxicam is a COX-2-preferential NSAID — it targets COX-2 more than COX-1 but is not fully selective. It is dosed once daily and is the most commonly prescribed NSAID in PI cases. Celecoxib is a COX-2-selective NSAID — it inhibits COX-2 with minimal COX-1 effect, providing the best GI safety profile of any available NSAID. Celecoxib also has an FDA approval for acute pain specifically, making it on-label for post-injury pain management.

Why would a PI patient be prescribed celecoxib instead of a cheaper NSAID like ibuprofen?

Celecoxib is typically chosen over non-selective NSAIDs like ibuprofen when the patient has GI risk factors (prior ulcers, concurrent anticoagulant use, age over 65, or previous GI bleeding on NSAIDs) or when the physician anticipates prolonged NSAID therapy. The COX-2 selectivity of celecoxib significantly reduces the risk of GI bleeding compared to ibuprofen or naproxen.

Why is a proton pump inhibitor (PPI) sometimes prescribed alongside an NSAID in a PI case?

PPI co-prescribing with NSAIDs — even COX-2-preferential agents like meloxicam — is a clinical standard of care when NSAID therapy is expected to be prolonged or when the patient has GI risk factors. The combination of an NSAID plus a PPI in the pharmacy record documents that the treating physician anticipated ongoing, extended anti-inflammatory therapy significant enough to require GI protection.

Are meloxicam and celecoxib covered under a pharmacy lien?

Yes. Both meloxicam and celecoxib are covered under LienScripts pharmacy liens when prescribed by a treating physician for injury-related inflammation and pain. Both are available as generics and are standard components of PI medication regimens. Their fill history is captured in the POGOS chronologically, documenting the duration of inflammatory pain treatment.